Skip to main content
$0.48 -$0.02 (-3.9%)

01:18 PM EDT on 06/27/22

Athenex, Inc. (NASDAQ:ATNX)

CAPS Rating: No stars

Current Price $0.48 Mkt Cap $55.9M
Open $0.52 P/E Ratio 0.00
Prev. Close $0.50 Div. (Yield) $0.00 (0.0%)
Daily Range $0.47 - $0.53 Volume 765,868
52-Wk Range $0.42 - $5.13 Avg. Daily Vol. 1,253,994

Caps

This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

4 Outperform
1 Underperform
 

All-Star Players

0 Outperform
1 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:ATNX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:ATNX VS S&P 500 (SPY)

NASDAQ:ATNX Summary

Fools bullish on NASDAQ:ATNX are also bullish on:

Fools bearish on NASDAQ:ATNX are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about ATNX.

Recs

0
Member Avatar mdriver78 (63.33) Submitted: 1/8/2021 2:41:14 PM : Outperform Start Price: $11.53 NASDAQ:ATNX Score: -98.44

Athenex (NASDAQ: ATNX) has taught the old dog new tricks, making it a safer, more effective treatment for cancer. The drug is an oral form of paclitaxel, a chemo drug that’s given intravenously. The company’s drug-delivery technology makes paclitaxel absorbable in the digestive system, so no injections are necessary, which is great for improving patient compliance and reducing the need for doctor’s visits.

That would be great on its own, but Athenex’s oral chemo drug has also proven to cause fewer side effects and greater survival in patients with metastatic breast cancer.

The company has a shot at eventually taking oral paclitaxel into the market for most if not all of the types of cancer this chemo drug is used for as standard of care — which includes earlier-stage breast cancer, gastric cancer, ovarian cancer and lung cancer..

The sales potential for this improved form of paclitaxel is easily over $1 billion per year — it’s a blockbuster drug in the waiting should the FDA approve it.

Moreover, the basic delivery technology — which promotes absorption via the oral route — is applicable to a number of other widely used chemotherapy compounds.

Athenex’s drug won’t have to wait long for a decision. It’s been under priority review at the FDA for treating metastatic breast cancer and the decision date is Feb. 28, 2021. That’s less than two months from now.

Even better, our Flash Approval Indicator is showing very positive options activity, sending a signal that there’s deep interest in this $1.1 billion-market-cap drug developer. Moreover, insider activity is strong, with insiders accumulating millions in shares over the past 10 months. It’s also completely one-sided, with no recorded sells going back over that same period.

Recs

0
Member Avatar Perseverance (< 20) Submitted: 1/4/2021 9:12:14 AM : Outperform Start Price: $10.95 NASDAQ:ATNX Score: -98.19

Strong pipeline for this cancer cure focused pharmaceutical company. FDA approval achieved in December 2020 for its first product with a large addressable market for Actinic Keratosis...aka pre-cancerous skin lesion. A second FDA approval is expected in February 2021 for its liquid chemotherapy (drink) for metastatic breast cancer. Not only does this company invent novel therapies, they also manufacture and distribute them.

Recs

0
Member Avatar DaytradingStars (34.49) Submitted: 5/31/2020 7:17:46 AM : Outperform Start Price: $11.13 NASDAQ:ATNX Score: -123.81

50%

Leaderboard

Find the members with the highest scoring picks in ATNX.

Score Leader

LazyHarlequin

LazyHarlequin (93.28) Score: +134.13

The Score Leader is the player with the highest score across all their picks in ATNX.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
LazyHarlequin 93.28 8/7/2019 Underperform 5Y $14.11 -96.59% +37.54% +134.13 1 Comment
Perseverance < 20 1/13/2021 Outperform 3Y $10.95 -95.60% +2.59% -98.19 1 Comment
mdriver78 63.33 1/8/2021 Outperform 5Y $11.53 -95.83% +2.62% -98.44 1 Comment
MaineMaker < 20 1/12/2021 Outperform 5Y $11.78 -95.91% +2.70% -98.61 0 Comment
DaytradingStars 34.49 6/1/2020 Outperform 5Y $11.13 -95.68% +28.13% -123.81 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for ATNX.